The potential cash and shares deal values Quantum’s shares at 82p each and the company at £150.3 million Christopher Furlong/Getty ImagesA troubled pharmaceutical company has agreed an offer from a rival at a price below its float level of less than three years ago when directors made millions of pounds selling shares. Quantum Pharma yesterday recommended a takeover from Clinigen Group, one of the biggest companies on Aim, in a cash and shares deal that values Quantum’s shares at 82p each and the company at £150.3 million. The potential acquisition is almost a fifth below the level at which the company floated on AIM in December 2014. The listing, handled by Zeus Capital, had enabled existing investors, including directors, to sell almost £30 million of shares. They included Andrew Scaife, chief executive at the time, who sold half his holding for £3.3 million, Martin Such,…

Source: The Times September 13, 2017 15:56 UTC